Huitai Medical Vice Chairman Cheng Zhenghui plans to sell up to 1.5% stake
On September 20, 2025, Huitai Medical announced that Vice Chairman and General Manager Cheng Zhenghui plans to sell up to 1.5% of total shares via block trades within three months starting 15 trading days after the announcement. Cheng holds about 16.68% of the company. This follows a prior 2% sale in September 2025 that netted approximately 700 million yuan. The reduction is for personal funding needs and is not expected to materially impact operations.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both sides agree this is not a panic sell or collapse, as the 1.5% stake reduction is modest and done through block trades.
- Both agree that Cheng Zhenghui is no longer in operational control after Mindray's acquisition, which changes the meaning of his share sale.
- Both acknowledge the 18-month gap between the Mindray acquisition and the first sale is consistent with standard lock-up periods in Chinese M&A.
Points of contention
- Eastern Agent argues the sale is a routine post-M&A adjustment within China's consolidating medical device sector, while Neutral Agent insists it still deserves scrutiny as an insider signal.
- Eastern Agent dismisses questions about the founder's reasons as 'Western media habits,' but Neutral Agent says investors have a right to ask why a major shareholder trims twice in six months.
- Neutral Agent emphasizes checking the current stock price relative to the 248 yuan sale price as key data, while Eastern Agent calls that speculative noise.
Blind spots
- Neither side checked the actual current stock price of Huitai Medical relative to the 248 yuan sale price, which could clarify whether the founder is selling into strength or weakness.
- Both sides overlooked the specific terms of the Mindray acquisition, such as any lock-up agreements or coordination between the founder and Mindray, which would settle whether the sales were planned.
- The debate ignored how other minority shareholders or institutional investors might react to this sale, which could affect market psychology beyond the founder's intent.
WorldAttention’s read
This debate boils down to a clash of perspectives: Eastern Agent sees the founder's share sale as a normal, planned step in China's medical device consolidation under Mindray, while Neutral Agent views it as a modest insider move that still warrants attention, especially regarding the stock price. Both agree it's not a crisis, but they disagree on whether the sale is a non-event or a signal. The biggest blind spot is that neither side checked the current stock price against the 248 yuan sale price, which would provide concrete data on the founder's timing. Ultimately, the real story isn't about national pride or market systems—it's about whether Huitai's fundamentals under Mindray justify its valuation, and that question remains unanswered.
Reporting timeline
Huitai Medical Vice Chairman, General Manager Plans to Reduce Stake by Up to 1.5%
Huitai Medical (688617.SH) announced on September 20 that its Vice Chairman and General Manager, Cheng Zhenghui, who is also a shareholder holding more than 5% of the company's shares, plans to reduce his stake. According to a notice received by the company, Cheng intends to sell up to 212.29 million shares, representing no more than 1.5% of the company's total share capital, through block trades. The reduction period will be within three months starting 15 trading days after the announcement date. The news was reported by Stockstar, citing a filing from the company.
Read sourceHuitai Medical founder Cheng Zhenghui plans to sell another 1.5% stake after Mindray acquisition
On September 20, 2025, Huitai Medical announced that co-founder and second-largest shareholder Cheng Zhenghui plans to reduce his stake by 1.5% through a block trade. Cheng, who also serves as vice chairman and general manager, directly holds 16.68% of the company's shares. This follows a previous 2% stake sale in September 2025, which netted approximately 700 million yuan at 248.20 yuan per share. Huitai Medical, a cardiac electrophysiology and interventional medical device company listed on the STAR Market in January 2021, was acquired by Mindray Medical in early 2024 for 6.652 billion yuan. After the acquisition, Mindray became the controlling shareholder with 24.61% of shares, and Cheng's stake dropped from 24.97% to 18.72%. The ongoing selling by the founding shareholder has drawn market attention.
Read sourceHuitai Medical General Manager Plans to Reduce Shareholding by Up to 1.5%
Huitai Medical announced on September 20 that its general manager, Cheng Zhenghui, plans to reduce his holdings in the company by no more than 1.5% of total shares. The reduction period is set from October 20, 2026, to January 19, 2027, with the shares coming from pre-IPO holdings and equity incentives. As of the announcement date, Cheng Zhenghui and his concert party Wen Yiming collectively hold 16.6895% of the company's total share capital. Cheng's most recent reduction occurred from September 3 to September 11, 2025, when he sold 2,820,275 shares (2% of total shares) at a price of RMB 248.20 per share. The announcement notes that the plan is subject to market conditions and stock price, creating uncertainty about timing, price, and quantity. The reduction is for Cheng's personal funding needs and is stated not to materially impact the company's governance or operations.
Read sourceShow 2 older updatesHide older updates
Huitai Medical Vice Chairman Plans to Reduce Holdings by No More Than 1.5% of Shares
On the evening of September 20, Huitai Medical announced that Vice Chairman Cheng Zhenghui plans to reduce his holdings in the company by no more than 1.5% of total shares. As of the disclosure date, Cheng Zhenghui held approximately 23.6008 million shares, representing about 16.68% of the company's current total share capital. The announcement was reported by Beijing Business Today and published on East Money's company news section. The planned reduction represents a modest portion of his overall stake, suggesting a partial divestment rather than a complete exit. The specific timeline and method for the share reduction were not detailed in the available text.
Read sourceHuitai Medical Vice Chairman and GM Zheng Chenghui Plans to Sell Up to 1.5% Stake
Huitai Medical (688617) announced on September 20 that its vice chairman and general manager, Zheng Chenghui, who holds approximately 16.68% of the company's shares, plans to reduce his stake. According to the company's filing, Zheng intends to sell no more than 212.29 million shares, equivalent to up to 1.5% of the company's total share capital, through block trades within three months starting 15 trading days after the announcement. The planned sale is a routine disclosure of an insider's intention to reduce holdings, as per Chinese securities regulations.